Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JORGE M VENEREO

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1144299009
CMS profile
324488
Location
DORAL, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$34.17

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $34.17 2

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Covidien LP $22.56 1
SANOFI-AVENTIS U.S. LLC $11.61 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JORGE M VENEREO

NPI 1144299009 · CMS profile ID 324488

Allopathic & Osteopathic Physicians / Internal Medicine

DORAL, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1144299009?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JORGE M VENEREO, NPI 1144299009, CMS profile ID 324488. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1144299009?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JORGE M VENEREO, NPI 1144299009, CMS profile ID 324488. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1144299009?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JORGE M VENEREO, NPI 1144299009, CMS profile ID 324488, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1144299009?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $34.17 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
SANOFI-AVENTIS U.S. LLC $11.6103/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694003883 CMS
Covidien LP $22.5603/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637001759 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $34.17 2
PY2020 $83.58 5
PY2021 $95.63 5
PY2022 $125.00 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022
Generated from
OP_DTL_GNRL_PGYR2022_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $978,346.35 79
PY2024 Principal investigator $750,186.73 535
PY2023 Recipient $250.00 1
PY2023 Principal investigator $1,161,263.89 753
PY2022 Recipient $450.00 1
PY2022 Principal investigator $433,849.06 425
PY2021 Recipient $437.46 1
PY2021 Principal investigator $229,625.48 182
PY2020 Principal investigator $282,764.54 64
PY2019 Principal investigator $543,958.67 209

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

535 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156688
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156694
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156696
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156698
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156700
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156702
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156704
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156706
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156708
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156710
Principal investigator 1 Janssen Research & Development, LLC $8,102.00 12/30/2024 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1078996503
Principal investigator 1 Janssen Research & Development, LLC $2,945.00 12/26/2024 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1078996493
Principal investigator 1 Janssen Research & Development, LLC $2,945.00 12/26/2024 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1078996501
Principal investigator 1 Janssen Research & Development, LLC $17,255.00 12/18/2024 Non-covered Recipient Entity
Pharmax Rsrch Clnc
67953964MDD3003 No dispute reported 06/30/2026 1078957405
Principal investigator 1 Janssen Research & Development, LLC $18,240.00 12/18/2024 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1078996477
Principal investigator 1 Alnylam Pharmaceuticals Inc. $10,550.60 12/06/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1121156758
Principal investigator 1 Alnylam Pharmaceuticals Inc. $58,274.30 12/06/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1121156760
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 12/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156672
Principal investigator 1 Janssen Research & Development, LLC $1,800.00 12/04/2024 Non-covered Recipient Entity
Pharmax Rsrch Clnc
67953964MDD3003 No dispute reported 06/30/2026 1078957129
Principal investigator 1 Alnylam Pharmaceuticals Inc. $260.00 12/02/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156676
Principal investigator 1 Janssen Research & Development, LLC $27,655.00 12/02/2024 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1078996491
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156690
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156712
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156714
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156716
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156718
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156720
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156722
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156724
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156726
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156728
Principal investigator 1 Janssen Research & Development, LLC $12,418.00 11/25/2024 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1078996485
Principal investigator 1 Alnylam Pharmaceuticals Inc. $204.00 11/18/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156680
Principal investigator 1 Janssen Research & Development, LLC $21,703.00 11/15/2024 Non-covered Recipient Entity
Pharmax Rsrch Clnc
67953964MDD3003 No dispute reported 06/30/2026 1078956817
Principal investigator 1 Janssen Research & Development, LLC $20,000.00 11/01/2024 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1078996507
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156692
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156730
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156732
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156734
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156736
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156738
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156740
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156742
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156744
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156746
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 10/28/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156668
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 10/28/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156754
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 10/28/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156756
Principal investigator 1 Janssen Research & Development, LLC $215.00 10/28/2024 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1078996499
Principal investigator 1 Janssen Research & Development, LLC $540.00 10/18/2024 Non-covered Recipient Entity
Pharmax Rsrch Clnc
67953964MDD3003 No dispute reported 06/30/2026 1078956987
Principal investigator 1 Janssen Research & Development, LLC $9,109.00 10/16/2024 Non-covered Recipient Entity
Pharmax Rsrch Clnc
67953964MDD3003 No dispute reported 06/30/2026 1078957327
Principal investigator 1 Alnylam Pharmaceuticals Inc. $793.00 10/14/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156678
Principal investigator 1 Alnylam Pharmaceuticals Inc. $955.00 10/14/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156682
Principal investigator 1 Alnylam Pharmaceuticals Inc. $978.00 10/14/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156684
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,481.00 10/14/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156686
Principal investigator 1 Janssen Research & Development, LLC $7,797.00 10/14/2024 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1078996509
Principal investigator 1 Janssen Research & Development, LLC $1,264.00 10/14/2024 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1078996515
Principal investigator 1 Alnylam Pharmaceuticals Inc. $272.00 10/09/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156674
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 10/02/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156670
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 10/02/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156748
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 10/02/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156750
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 10/02/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156752
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156390
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156392
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156394
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156396
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156398
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156400
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156402
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156404
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156406
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156410
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156412
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156414
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156416
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156418
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156462
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156476
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156478
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156482
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156484
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156486
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156488
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156490
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156492
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156494
Principal investigator 1 Janssen Research & Development, LLC $19,937.00 09/20/2024 Non-covered Recipient Entity
Pharmax Rsrch Clnc
67953964MDD3003 No dispute reported 06/30/2026 1078957679
Principal investigator 1 Janssen Research & Development, LLC $7,173.00 09/16/2024 Non-covered Recipient Entity
Pharmax Rsrch Clnc
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1078957547
Principal investigator 1 Alnylam Pharmaceuticals Inc. $136.00 09/13/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156302
Principal investigator 1 Alnylam Pharmaceuticals Inc. $606.00 09/13/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156308
Principal investigator 1 Alnylam Pharmaceuticals Inc. $146.00 09/13/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156320
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6,798.00 09/11/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1121156350
Principal investigator 1 Alnylam Pharmaceuticals Inc. $146.00 09/09/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156318
Principal investigator 1 Alnylam Pharmaceuticals Inc. $174.00 09/09/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156342
Principal investigator 1 Alnylam Pharmaceuticals Inc. $218.00 09/09/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156344
Principal investigator 1 Alnylam Pharmaceuticals Inc. $138.00 09/09/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156348
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 09/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156306
Principal investigator 1 Alnylam Pharmaceuticals Inc. $511.00 09/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156314
Principal investigator 1 Alnylam Pharmaceuticals Inc. $73.00 09/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156316
Principal investigator 1 Alnylam Pharmaceuticals Inc. $87.00 09/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156334
Principal investigator 1 Alnylam Pharmaceuticals Inc. $109.00 09/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156336
Principal investigator 1 Alnylam Pharmaceuticals Inc. $837.00 09/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156338
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,664.00 09/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156340
Principal investigator 1 Alnylam Pharmaceuticals Inc. $69.00 09/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156346
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 09/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156512
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,664.00 09/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156562
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,664.00 09/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156564
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,664.00 09/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156566
Principal investigator 1 Janssen Research & Development, LLC $1,125.00 09/04/2024 Non-covered Recipient Entity
Pharmax Rsrch Clnc
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1078957361
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156354
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156356
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156358
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156360
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156362
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156364
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156366
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156368
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156370
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156372
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156374
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156420
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156422
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156424
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156428
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156430
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156432
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156434
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156436
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156438
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156440
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156442
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156444
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156496
Principal investigator 1 Janssen Research & Development, LLC $17,563.00 08/27/2024 Non-covered Recipient Entity
Pharmax Rsrch Clnc
67953964MDD3003 No dispute reported 06/30/2026 1078957083
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,171.00 08/21/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1121156352
Principal investigator 1 GlaxoSmithKline, LLC. $10,648.48 08/21/2024 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 1127549780
Principal investigator 1 Janssen Research & Development, LLC $24,351.00 08/21/2024 Non-covered Recipient Entity
Pharmax Rsrch Clnc
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1078957255
Principal investigator 1 Janssen Research & Development, LLC $900.00 08/16/2024 Non-covered Recipient Entity
Pharmax Rsrch Clnc
67953964MDD3003 No dispute reported 06/30/2026 1078956767
Principal investigator 1 Alnylam Pharmaceuticals Inc. $978.00 08/14/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156324
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,664.00 08/14/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156326
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,250.40 08/14/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156328
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,266.00 08/14/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156330
Principal investigator 1 Alnylam Pharmaceuticals Inc. $837.00 08/14/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156332
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,664.00 08/14/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156498
Principal investigator 1 Alnylam Pharmaceuticals Inc. $978.00 08/14/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156514
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,664.00 08/14/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156516
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,664.00 08/14/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156518
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,664.00 08/14/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156520
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,266.00 08/14/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156522
Principal investigator 1 Alnylam Pharmaceuticals Inc. $978.00 08/14/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156524
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,664.00 08/14/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156526
Principal investigator 1 Alnylam Pharmaceuticals Inc. $978.00 08/14/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156528
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,664.00 08/14/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156530
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,664.00 08/14/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156532
Principal investigator 1 Alnylam Pharmaceuticals Inc. $978.00 08/14/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156534
Principal investigator 1 Alnylam Pharmaceuticals Inc. $978.00 08/14/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156536
Principal investigator 1 Alnylam Pharmaceuticals Inc. $978.00 08/14/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156538
Principal investigator 1 Alnylam Pharmaceuticals Inc. $978.00 08/14/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156540
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,266.00 08/14/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156542
Principal investigator 1 Alnylam Pharmaceuticals Inc. $978.00 08/14/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156544
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,664.00 08/14/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156546
Principal investigator 1 Alnylam Pharmaceuticals Inc. $978.00 08/14/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156548
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,664.00 08/14/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156550
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,664.00 08/14/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156552
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,664.00 08/14/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156554
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,664.00 08/14/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156556
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,664.00 08/14/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156558
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,664.00 08/14/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156560
Principal investigator 1 Janssen Research & Development, LLC $386.00 08/07/2024 Non-covered Recipient Entity
Pharmax Rsrch Clnc
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1078956923
Principal investigator 1 Alnylam Pharmaceuticals Inc. $292.00 08/02/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156312
Principal investigator 1 Alnylam Pharmaceuticals Inc. $326.00 08/02/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156322
Principal investigator 1 Janssen Research & Development, LLC $266.00 08/02/2024 Non-covered Recipient Entity
Pharmax Rsrch Clnc
67953964MDD3003 No dispute reported 06/30/2026 1078957573
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156376
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156378
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156380
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156382
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156384
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156386
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156388
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156408
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156426
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156446
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156448
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156450
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156452
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156454
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156456
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156458
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156460
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156464
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156466
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156468
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156470
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156472
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156474
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156480
Principal investigator 1 Alnylam Pharmaceuticals Inc. $476.00 07/26/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156300
Principal investigator 1 Janssen Research & Development, LLC $12,678.00 07/22/2024 Non-covered Recipient Entity
Pharmax Rsrch Clnc
67953964MDD3003 No dispute reported 06/30/2026 1078956979
Principal investigator 1 Janssen Research & Development, LLC $20,765.00 07/12/2024 Non-covered Recipient Entity
Pharmax Rsrch Clnc
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1078957505
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 07/01/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156304
Principal investigator 1 Alnylam Pharmaceuticals Inc. $146.00 07/01/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156310
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 07/01/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156500
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 07/01/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156502
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 07/01/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156504
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 07/01/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156506
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 07/01/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156508
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 07/01/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156510
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156252
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156254
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156256
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156258
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156260
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156262
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156264
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156266
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156268
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156270
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156272
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156274
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156276
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156278
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156280
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156282
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156284
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156286
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156288
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156290
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156292
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156294
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156296
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156298
Principal investigator 1 Alnylam Pharmaceuticals Inc. $707.00 06/21/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156124
Principal investigator 1 Janssen Research & Development, LLC $12,794.00 06/21/2024 Non-covered Recipient Entity
Pharmax Rsrch Clnc
67953964MDD3003 No dispute reported 06/30/2026 1078957643
Principal investigator 1 Alnylam Pharmaceuticals Inc. $68.00 06/17/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156072
Principal investigator 1 Janssen Research & Development, LLC $17,522.00 06/12/2024 Non-covered Recipient Entity
Pharmax Rsrch Clnc
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1078957135
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 06/03/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156134
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 06/03/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156178
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156094
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156096
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156150
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156152
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156154
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156156
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156158
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156160
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156162
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156164
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156166
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156168
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156170
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156216
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156218
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156220
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156222
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156226
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156228
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156230
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156232
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156238
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156242
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156248
Principal investigator 1 Alnylam Pharmaceuticals Inc. $73.00 05/17/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156074
Principal investigator 1 Alnylam Pharmaceuticals Inc. $219.00 05/17/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156076
Principal investigator 1 Alnylam Pharmaceuticals Inc. $87.00 05/17/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156116
Principal investigator 1 Alnylam Pharmaceuticals Inc. $203.00 05/17/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156118
Principal investigator 1 Alnylam Pharmaceuticals Inc. $489.00 05/17/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156120
Principal investigator 1 Alnylam Pharmaceuticals Inc. $109.00 05/17/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156122
Principal investigator 1 Janssen Research & Development, LLC $11,546.00 05/17/2024 Non-covered Recipient Entity
Pharmax Rsrch Clnc
67953964MDD3003 No dispute reported 06/30/2026 1078957313
Principal investigator 1 Janssen Research & Development, LLC $21,491.00 05/13/2024 Non-covered Recipient Entity
Pharmax Rsrch Clnc
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1078957539
Principal investigator 1 Alnylam Pharmaceuticals Inc. $408.00 05/06/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156066
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 05/01/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156114
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 05/01/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156172
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 05/01/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156174
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 05/01/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156176
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 05/01/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156246
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,430.00 04/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156084
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156086
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156088
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156140
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156142
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156144
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156146
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156148
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156180
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,430.00 04/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156182
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,430.00 04/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156184
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,430.00 04/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156186
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,430.00 04/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156188
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,430.00 04/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156190
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156192
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156194
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156196
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156198
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156200
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156202
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156204
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156206
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156208
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156210
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156212
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156214
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156224
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156236
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156240
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156244
Principal investigator 1 Alnylam Pharmaceuticals Inc. $146.00 04/22/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156078
Principal investigator 1 Alnylam Pharmaceuticals Inc. $195.00 04/22/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156080
Principal investigator 1 Alnylam Pharmaceuticals Inc. $292.00 04/22/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156082
Principal investigator 1 Alnylam Pharmaceuticals Inc. $476.00 04/22/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156126
Principal investigator 1 Alnylam Pharmaceuticals Inc. $174.00 04/22/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156128
Principal investigator 1 Alnylam Pharmaceuticals Inc. $489.00 04/22/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156130
Principal investigator 1 Alnylam Pharmaceuticals Inc. $218.00 04/22/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156132
Principal investigator 1 Alnylam Pharmaceuticals Inc. $138.00 04/22/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156138
Principal investigator 1 Janssen Research & Development, LLC $8,293.00 04/22/2024 Non-covered Recipient Entity
Pharmax Rsrch Clnc
67953964MDD3003 No dispute reported 06/30/2026 1078957027
Principal investigator 1 Janssen Research & Development, LLC $21,254.00 04/17/2024 Non-covered Recipient Entity
Pharmax Rsrch Clnc
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1078956901
Principal investigator 1 Alnylam Pharmaceuticals Inc. $303.00 04/12/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156112
Principal investigator 1 Alnylam Pharmaceuticals Inc. $438.00 04/05/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156068
Principal investigator 1 Alnylam Pharmaceuticals Inc. $204.00 04/05/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156070
Principal investigator 1 Alnylam Pharmaceuticals Inc. $132.00 04/05/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156090
Principal investigator 1 Alnylam Pharmaceuticals Inc. $176.00 04/05/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156092
Principal investigator 1 Alnylam Pharmaceuticals Inc. $238.00 04/05/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156098
Principal investigator 1 Alnylam Pharmaceuticals Inc. $522.00 04/05/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156100
Principal investigator 1 Alnylam Pharmaceuticals Inc. $203.00 04/05/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156102
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,304.00 04/05/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156104
Principal investigator 1 Alnylam Pharmaceuticals Inc. $436.00 04/05/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156106
Principal investigator 1 Alnylam Pharmaceuticals Inc. $414.00 04/05/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156136
Principal investigator 1 Alnylam Pharmaceuticals Inc. $132.00 04/05/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156234
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 04/01/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156108
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,767.00 04/01/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156110
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 04/01/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156250
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155884
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155886
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155888
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155890
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155892
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155894
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155896
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155898
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155900
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155902
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155904
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155906
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155908
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155910
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155912
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155914
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155916
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155972
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155974
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155980
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155982
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155984
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155986
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155988
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155990
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155992
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155994
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155996
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155998
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156000
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156002
Principal investigator 1 Alnylam Pharmaceuticals Inc. $780.00 03/25/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155734
Principal investigator 1 Alnylam Pharmaceuticals Inc. $584.00 03/25/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155736
Principal investigator 1 Janssen Research & Development, LLC $5,144.00 03/22/2024 Non-covered Recipient Entity
Pharmax Rsrch Clnc
67953964MDD3003 No dispute reported 06/30/2026 1078957305
Principal investigator 1 Janssen Research & Development, LLC $18,078.00 03/20/2024 Non-covered Recipient Entity
Pharmax Rsrch Clnc
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1078957331
Principal investigator 1 Alnylam Pharmaceuticals Inc. $68.00 03/11/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155702
Principal investigator 1 Alnylam Pharmaceuticals Inc. $66.00 03/11/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155704
Principal investigator 1 Alnylam Pharmaceuticals Inc. $61.00 03/11/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155706
Principal investigator 1 Alnylam Pharmaceuticals Inc. $64.00 03/11/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155708
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/11/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155710
Principal investigator 1 Alnylam Pharmaceuticals Inc. $195.00 03/11/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155712
Principal investigator 1 Alnylam Pharmaceuticals Inc. $369.00 03/11/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155714
Principal investigator 1 Alnylam Pharmaceuticals Inc. $136.00 03/11/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155716
Principal investigator 1 Alnylam Pharmaceuticals Inc. $68.00 03/11/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155764
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,767.00 03/08/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155718
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,784.00 03/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155682
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,231.00 03/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155684
Principal investigator 1 Alnylam Pharmaceuticals Inc. $978.00 03/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155686
Principal investigator 1 Alnylam Pharmaceuticals Inc. $837.00 03/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155688
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,266.00 03/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155690
Principal investigator 1 Alnylam Pharmaceuticals Inc. $978.00 03/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155784
Principal investigator 1 Alnylam Pharmaceuticals Inc. $978.00 03/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155786
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,266.00 03/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155788
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,266.00 03/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155790
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,266.00 03/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155792
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,266.00 03/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155794
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,784.00 03/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155796
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,784.00 03/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155798
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,784.00 03/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155800
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,784.00 03/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155802
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,784.00 03/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155804
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,784.00 03/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155806
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,784.00 03/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155808
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,784.00 03/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155810
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,784.00 03/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155812
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,784.00 03/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155814
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,784.00 03/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155816
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,784.00 03/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155818
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,784.00 03/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155834
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,231.00 03/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155836
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,231.00 03/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155838
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,231.00 03/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155840
Principal investigator 1 Alnylam Pharmaceuticals Inc. $978.00 03/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155842
Principal investigator 1 Alnylam Pharmaceuticals Inc. $978.00 03/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155844
Principal investigator 1 Alnylam Pharmaceuticals Inc. $978.00 03/04/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155846
Principal investigator 1 Alnylam Pharmaceuticals Inc. $66.00 03/01/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155662
Principal investigator 1 Alnylam Pharmaceuticals Inc. $61.00 03/01/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155664
Principal investigator 1 Alnylam Pharmaceuticals Inc. $68.00 03/01/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155666
Principal investigator 1 Alnylam Pharmaceuticals Inc. $64.00 03/01/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155668
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/01/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155670
Principal investigator 1 Alnylam Pharmaceuticals Inc. $195.00 03/01/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155672
Principal investigator 1 Alnylam Pharmaceuticals Inc. $505.00 03/01/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155674
Principal investigator 1 Alnylam Pharmaceuticals Inc. $369.00 03/01/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155676
Principal investigator 1 Alnylam Pharmaceuticals Inc. $68.00 03/01/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155876
Principal investigator 1 Alnylam Pharmaceuticals Inc. $68.00 03/01/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155878
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156004
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156006
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156008
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156010
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156012
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156014
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156016
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156018
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156020
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156022
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156024
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156026
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156028
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156030
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156032
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156034
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156036
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156038
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156040
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156042
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156044
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156046
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156048
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156050
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156052
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156054
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156056
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156058
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121156060
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156062
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121156064
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,020.00 02/23/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155744
Principal investigator 1 Alnylam Pharmaceuticals Inc. $87.00 02/23/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155746
Principal investigator 1 Alnylam Pharmaceuticals Inc. $69.00 02/23/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155748
Principal investigator 1 Alnylam Pharmaceuticals Inc. $195.00 02/23/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155750
Principal investigator 1 Alnylam Pharmaceuticals Inc. $489.00 02/23/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155752
Principal investigator 1 Alnylam Pharmaceuticals Inc. $219.00 02/23/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155754
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 02/23/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155756
Principal investigator 1 Alnylam Pharmaceuticals Inc. $109.00 02/23/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155758
Principal investigator 1 Alnylam Pharmaceuticals Inc. $975.00 02/23/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155760
Principal investigator 1 Alnylam Pharmaceuticals Inc. $949.00 02/23/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155762
Principal investigator 1 Janssen Research & Development, LLC $4,653.00 02/16/2024 Non-covered Recipient Entity
Pharmax Rsrch Clnc
67953964MDD3003 No dispute reported 06/30/2026 1078957451
Principal investigator 1 Janssen Research & Development, LLC $6,522.00 02/12/2024 Non-covered Recipient Entity
Pharmax Rsrch Clnc
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1078957419
Principal investigator 1 AstraZeneca UK Limited $10,681.95 02/09/2024 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment No dispute reported 06/30/2026 1110839700
Principal investigator 1 Janssen Research & Development, LLC $7,040.00 02/09/2024 Non-covered Recipient Entity
Pharmax Rsrch Clnc
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1078956847
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 02/02/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155658
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,767.00 02/02/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155660
Principal investigator 1 Alnylam Pharmaceuticals Inc. $837.00 02/02/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155692
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,664.00 02/02/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155694
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,266.00 02/02/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155696
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,266.00 02/02/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155766
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,266.00 02/02/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155768
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,266.00 02/02/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155770
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,266.00 02/02/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155772
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,266.00 02/02/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155774
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,266.00 02/02/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155776
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,266.00 02/02/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155778
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,266.00 02/02/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155780
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,266.00 02/02/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155782
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 02/02/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155848
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 02/02/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155850
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 02/02/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155852
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 02/02/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155854
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 02/02/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155856
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 02/02/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155858
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,767.00 02/02/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155860
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,767.00 02/02/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155862
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,767.00 02/02/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155864
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,767.00 02/02/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155866
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,767.00 02/02/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155868
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,767.00 02/02/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155870
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,767.00 02/02/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155872
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,767.00 02/02/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155874
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155880
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155882
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155918
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155920
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155922
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155924
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155926
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155928
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155930
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155932
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155934
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155936
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155938
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155940
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155942
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155944
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155946
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155948
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155950
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155952
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155954
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155956
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155958
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155960
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155962
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155964
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155966
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155968
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155970
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155976
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155978
Principal investigator 1 Alnylam Pharmaceuticals Inc. $87.00 01/24/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155724
Principal investigator 1 Alnylam Pharmaceuticals Inc. $69.00 01/24/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155726
Principal investigator 1 Alnylam Pharmaceuticals Inc. $163.00 01/24/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155728
Principal investigator 1 Alnylam Pharmaceuticals Inc. $73.00 01/24/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155730
Principal investigator 1 Alnylam Pharmaceuticals Inc. $109.00 01/24/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155732
Principal investigator 1 Alnylam Pharmaceuticals Inc. $780.00 01/19/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155720
Principal investigator 1 Alnylam Pharmaceuticals Inc. $657.00 01/19/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155722
Principal investigator 1 Janssen Research & Development, LLC $6,583.00 01/17/2024 Non-covered Recipient Entity
Pharmax Rsrch Clnc
67953964MDD3003 No dispute reported 06/30/2026 1078956821
Principal investigator 1 Janssen Research & Development, LLC $15,608.00 01/12/2024 Non-covered Recipient Entity
Pharmax Rsrch Clnc
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1078956831
Principal investigator 1 Alnylam Pharmaceuticals Inc. $68.00 01/10/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155678
Principal investigator 1 Alnylam Pharmaceuticals Inc. $101.00 01/10/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155680
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 01/03/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155698
Principal investigator 1 Alnylam Pharmaceuticals Inc. $153.00 01/03/2024 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155700
Principal investigator 1 Alnylam Pharmaceuticals Inc. $837.00 01/03/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155738
Principal investigator 1 Alnylam Pharmaceuticals Inc. $978.00 01/03/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155740
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,845.00 01/03/2024 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155742